CRISPR And Cas Gene Market Revenue Growth Expected to Reach $13.09 Billion by 2030 with 22.3% CAGR
The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Expansion Is Predicted For The CRISPR And Cas Gene Market Between 2026 And 2030?
The crispr and cas gene market size has seen substantial growth recently. It is projected to expand from $4.81 billion in 2025 to $5.86 billion in 2026, achieving a compound annual growth rate (CAGR) of 21.8%. Historically, this expansion can be linked to several factors including the groundbreaking discovery of crispr cas systems, lower gene editing expenses, broader adoption in academic research, the availability of research kits, and backing from government funding.
The crispr and cas gene market is anticipated to experience substantial growth over the next few years, with its size expected to reach $13.1 billion by 2030, driven by a compound annual growth rate (CAGR) of 22.3%. This expansion during the forecast period is primarily attributed to the clinical implementation of gene editing, the spread of personalized medicine, the emergence of biotech startups, increased funding for research, and improvements in delivery mechanisms. Key trends foreseen include the wider application of gene editing in research, its expanding utilization in cell line engineering, increased integration into drug discovery processes, the creation of advanced crispr libraries, and the rise of bespoke gene editing services.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13632&type=smp
What Major Drivers Are Influencing Demand In The CRISPR And Cas Gene Market?
An increasing emphasis on personalized therapy is anticipated to boost the expansion of the CRISPR and Cas gene markets in the future. Personalized therapy is defined as a medical approach utilizing an individual’s genetic makeup to inform decisions regarding disease diagnosis, treatment, and prevention. CRISPR and the Cas gene, especially Cas9, find application in personalized medicine by allowing accurate alterations to a person’s genetic material, thereby offering significant potential for advances in creating customized treatments for genetic conditions, cancer, and diverse medical issues. As an illustration, in February 2024, data from the Personalized Medicine Coalition (PMC), a US-based organization, revealed that in 2023, the FDA approved 16 new personalized therapies for rare disease patients, which is a rise from the six treatments sanctioned in 2022. Consequently, the escalating need for personalized therapy will fuel the development of the CRISPR and Cas gene markets.
Which Market Segments Are Examined In The CRISPR And Cas Gene Market Study?
The crispr and cas gene market covered in this report is segmented –
1) By Product Type: Kits And Enzymes, Libraries, Design Tool, Antibodies, Other Products Types
2) By Service Type: Cell Line Engineering, gRNA Design, Microbial Gene Editing, DNA Synthesis
3) By Application: Clinical, Financial, Operational And Administrative
4) By End Use: Biotechnology And Pharmaceutical Companies, Academics And Government Research Institutes, Contract Research Organizations (CROs)
Subsegments:
1) By Kits And Enzymes: CRISPR Kits, Cas Enzymes, Grna Synthesis Kits
2) By Libraries: CRISPR Libraries For Gene Knockout, CRISPR Libraries For Gene Activation, Sgrna Libraries
3) By Design Tools: Online Design Platforms, Software For CRISPR Guide RNA Design, Custom Design Services
4) By Antibodies: Antibodies For Cas Proteins, Antibodies For Detection Of Edited Cells, Secondary Antibodies For Immunoassays
5) By Other Product Types: Delivery Systems, CRISPR-Related Consumables, Control Plasmids And Reagents
Which Trends Are Influencing The CRISPR And Cas Gene Market?
Major companies engaged in the CRISPR and Cas gene markets are developing innovative products like CRISPR-based cell-based gene therapy to enhance their product offerings and achieve a competitive advantage. This therapy involves using CRISPR gene-editing technology to modify or correct genetic material within cells, providing a targeted and potentially transformative approach to treating genetic disorders, diseases, and other medical conditions at the cellular level. For example, in December 2023, Vertex Pharmaceuticals Incorporated, a US-based biopharmaceutical company, received approval for CASGEVY (exagamglogene autotemcel [exa-cel]) from the U.S. Food and Drug Administration (FDA). CASGEVY is a CRISPR/Cas9 genome-edited gene therapy for the management of sickle cell disease (SCD) in individuals aged 12 and above who experience recurrent vaso-occlusive crises. CASGEVY is a first-of-its-kind medication that has the potential to be a one-time transformational therapy for qualified sickle cell patients. Since CASGEVY administration necessitates specific training in stem cell transplantation, Vertex is collaborating with experienced institutions to establish a network of independently owned, approved treatment centers (ATCs) across the United States to provide CASGEVY to patients.
Who Are The Primary Competitors In The CRISPR And Cas Gene Market?
Major companies operating in the crispr and cas gene market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc, AstraZeneca plc, Danaher Corporation, Lonza Group AG, Bio-Rad Laboratories Inc., eGenesis, Novartis Institutes for BioMedical Research, GenScript, Takara Bio Inc., Merck KGaA, Horizon Discovery Group Plc, Beam Therapeutics Inc, Intellia Therapeutics Inc, New England BioLabs, Recursion Pharmaceuticals Inc, Caribou Biosciences Inc, Cellectis S.A., Editas Medicine Inc, CRISPR Therapeutics AG, Mammoth Biosciences, Inscripta Inc, Prime Medicine Inc, Precision BioSciences Inc, Sangamo Therapeutics Inc.
Read the full crispr and cas gene market report here:
https://www.thebusinessresearchcompany.com/report/crispr-and-cas-gene-global-market-report
Which Region Shows The Strongest Potential For Future Growth In The CRISPR And Cas Gene Market?
North America was the largest region in the CRISPR and Cas gene market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the crispr and cas gene market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored CRISPR And Cas Gene Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=13632&type=smp
Browse Through More Reports Similar to the Global CRISPR And Cas Gene Market 2026, By The Business Research Company
Cranial Fixation And Stabilization Devices Global Market Report
Cerebrospinal Fluid Management Csf Devices And Equipment Global Market Report
Assistive Technologies For Visually Impaired Global Market Report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
